Sector News

Merck KGaA appoints pharma head Oschmann as deputy CEO

September 18, 2014
Life sciences
(Reuters) – German drugs and chemicals maker Merck KGaA appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive, it said on Thursday.
Oschmann, 57, will share strategic management functions and representation of the company with CEO Karl-Ludwig Kley as of Jan. 1, 2015, it said.
The promotion puts Oschmann in the frame to possibly succeed Kley, whose contract runs until September 2016.
Belen Garijo, 54, will take over leadership of the entire pharma business, according to the statement. Garijo is already CEO of Merck’s biopharmaceutical division, Merck Serono, to which she will add consumer health, allergy treatments and biosimilars.
(Reporting by Georgina Prodhan; Editing by Ludwig Burger)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]